Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alzheimer's disease
Biotech
MapLight raises $373M to plot phase 2 journey for Cobenfy rival
The biotech has started midphase studies in schizophrenia and Alzheimer’s disease psychosis in recent weeks.
Nick Paul Taylor
Jul 28, 2025 10:23am
Roche nets EU approval for blood test to rule out Alzheimer's
Jul 25, 2025 11:00am
Acumen taps JCR’s brain barrier tech for $555M Alzheimer’s deal
Jul 15, 2025 8:01am
Quest to carry Fujirebio’s FDA-cleared Alzheimer’s blood test
Jul 11, 2025 11:40am
INmune flunks Alzheimer’s trial, focuses on subgroup efficacy
Jun 30, 2025 8:50am
GE HealthCare's PET agent Vizamyl expands reach in Alzheimer's
Jun 27, 2025 9:45am
